Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · September 17, 2022

Efficacy and Safety of Dapagliflozin According to Frailty in Patients With HF



Additional Info

Efficacy and Safety of Dapagliflozin According to Frailty in Patients with Heart Failure: A Prespecified Analysis of the DELIVER Trial
Circulation 2022 Aug 27;[EPub Ahead of Print], JH Butt, PS Jhund, J Belohlávek, RA de Boer, CE Chiang, AS Desai, J Drożdzż, AF Hernandez, SE Inzucchi, T Katova, M Kitakaze, MN Kosiborod, CSP Lam, AM Langkilde, D Lindholm, E Bachus, F Martinez, B Merkely, M Petersson, JFK Saraiva, SJ Shah, M Vaduganathan, O Vardeny, U Wilderäng, BL Claggett, SD Solomon, JJV McMurray

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading